If you’ve come across the word orforglipron – in a news article, on social media, or in a conversation about weight management medication – and you’re not sure what it is, this is the place to start.
Orforglipron is a new daily oral medication for weight management, developed by Eli Lilly. In the United States it was approved in April 2026 and is available under the brand name Foundayo. In the UK it is currently going through regulatory review by the MHRA. It is not yet licensed here, but it is anticipated to become available in the UK later in 2026, subject to that approval.
What makes it different?
Most people who have heard of injectable weight management treatments know them as Wegovy and Mounjaro – the two most widely used in the UK. Orforglipron is in the same class of medication, but it is taken as a once-daily tablet, not an injection.
That matters for a straightforward reason: a significant proportion of people who could benefit from GLP-1 treatment have avoided it because of the needle. Orforglipron removes that barrier.
But it is also a different type of molecule from existing oral GLP-1 options. Unlike the Wegovy Pill (oral semaglutide), which is a peptide that requires a strict morning fasting protocol to absorb properly, orforglipron is a small-molecule drug. That means it does not need an absorption enhancer, does not degrade in the stomach, and can be taken at any time of day – with or without food, alongside other medications, without any timing restrictions. It’s recommended to be taken at the same time each day.
For many people, that flexibility is the practical difference that makes daily medication sustainable.
How does it work?
Orforglipron is a GLP-1 receptor agonist. It works by mimicking GLP-1, a hormone naturally produced in the gut after eating, which signals to the brain that you are full, slows gastric emptying, and helps regulate blood sugar.
The result, in clinical terms, is reduced appetite and improved metabolic function. In practical terms, it is medication that supports weight management by changing how hunger and fullness are experienced – not by willpower alone.
How effective is it?
Clinical trials showed around 12.4% average weight loss at the highest dose over 72 weeks. Individual results may vary. That is a clinically meaningful result, broadly comparable to injectable semaglutide (Wegovy injection).
Orforglipron also has the strongest maintenance evidence in the oral class. The ATTAIN-MAINTAIN trial, published in Nature Medicine in May 2026, specifically tested what happens when people who had been on injectable treatment switch to orforglipron for maintenance. People switching from the Wegovy injection maintained 79% of their weight loss at 52 weeks, compared with 38% in those who stopped active treatment. People switching from Mounjaro maintained 75%, compared with 49% on placebo.
For people already on injectable treatment and thinking about whether a switch to an oral medication is possible, that data is directly relevant. Switching to the right oral treatment, with proper clinical support, does not mean losing the progress you’ve worked for.
How is it taken?
Once daily, orally. Any time of day – just take it at the same time each day. With or without food. No water restrictions. No timing separation from other oral medications.
This is meaningfully simpler than the Wegovy Pill’s dosing requirements, and it is one of the reasons orforglipron is considered a stronger fit for people with irregular routines – shift workers, carers, frequent travellers, or anyone on multiple daily medications.
Like all weight management medications of this type, orforglipron uses a gradual titration schedule, starting at a low dose and increasing over time. This is standard practice and helps the body adjust, reducing the likelihood of side effects during the early weeks of treatment.
If you are already on an injectable weight loss medication such as Wegovy or Mounjaro, you may start on a higher dose, depending on your current dose. Your Clinician will advise what options are available to you.
What are the side effects?
The most common side effects are gastrointestinal – nausea, constipation, diarrhoea, vomiting and abdominal discomfort. These are consistent with the broader GLP-1 class and are typically mild to moderate in severity. They are most common during dose escalation and tend to improve as the body adjusts.
Because orforglipron does not require a fasting protocol, real-world drug absorption is more predictable than with the Wegovy Pill, which can mean a more consistent side effect profile.
Is orforglipron available in the UK?
Not yet. Orforglipron is currently under review by the MHRA and has not yet been granted a UK marketing authorisation. Any website or provider claiming to sell orforglipron in the UK prior to that approval is operating outside the regulatory framework and should be avoided. Unlicensed products carry serious safety risks.
UK availability is anticipated later in 2026, subject to MHRA approval. CheqUp will offer orforglipron as part of its programme as soon as it is available and approved. ou can join the waitlist to hear first.
Join waitlist
Is it the same as Foundayo?
Foundayo is the brand name under which orforglipron is sold in the United States. The UK brand name has not yet been confirmed. This page will be updated when it is. For now, orforglipron is the name to know.
How does it compare to the Wegovy Pill?
Both are once-daily oral weight management treatments. The key differences:
The Wegovy Pill (oral semaglutide) has higher headline efficacy – around 16.6% average weight loss at 25mg over 64 weeks versus around 12.4% for orforglipron – and carries a licensed cardiovascular indication for adults with obesity and established heart disease. But it requires a strict morning fasting protocol that a significant number of people find difficult to maintain consistently.
Orforglipron has no such restrictions. It has the stronger maintenance evidence, particularly for people switching from an injectable. It is the better practical fit for anyone whose daily routine makes a consistent morning ritual difficult to sustain.
Which is right for you is a clinical decision, made with you by your clinical team based on your profile, your routine and your goals. Individual results may vary for both treatments.
What happens next?
Orforglipron is expected to become available in the UK later in 2026, subject to MHRA approval. CheqUp will be offering it through its programme – one clinical team, one coach, everything included – as soon as it is available. Join the waitlist to be among the first to hear when it launches and what it costs.
*This article is for informational purposes. Orforglipron is not yet licensed in the UK. All treatment decisions are made by CheqUp’s clinical team based on your individual profile. Product availability is subject to MHRA approval. Clinical trial figures represent population averages; individual results will vary.*
